Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28628118 | 0.84 | KMT2A (0.43) | KMT2AADORA3CYP1A2POLBFAAH | |
| SCHEMBL28923147 | 0.83 | KMT2A (0.42) | KMT2AADORA3CYP1A2TP53POLB | |
| SCHEMBL28923148 | 0.83 | KMT2A (0.42) | KMT2AADORA3CYP1A2TP53POLB | |
| SCHEMBL31389863 | 0.77 | ATM (0.43) | KMT2ACYP1A2TP53POLBFAAH | |
| SCHEMBL31389606 | 0.76 | KMT2A (0.44) | KMT2ACYP1A2POLBFAAHGAA | |
| SCHEMBL27152236 | 0.75 | KMT2A (0.46) | KMT2AADORA3CYP1A2POLBFAAH | |
| SCHEMBL31066543 | 0.73 | ALDH1A1 (0.38) | KMT2AADORA3CYP1A2POLBMAPT | |
| SCHEMBL2927030 | 0.72 | CYP1A2 (0.41) | KMT2AADORA3CYP1A2POLBGAA | |
| SCHEMBL2929174 | 0.72 | NPC1 (0.41) | KMT2ACYP1A2GAA | |
| SCHEMBL27146168 | 0.72 | KMT2A (0.38) | KMT2ACYP1A2TP53FAAHGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360145-A1 | CSF-1R INHIBITORS AND USES THEREOF | MYROBALAN THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4539933-A1 | CSF-1R INHIBITORS AND USES THEREOF | Myrobalan Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119790038-A | CSF-1R inhibitors and uses thereof | 迈巴制药公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2023241608-A1 | CSF-1R INHIBITORS AND USES THEREOF | MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360145-A1 | CSF-1R INHIBITORS AND USES THEREOF | CSF1R, CSF3R, IL1RN | KMT2A 2008/4885ADORA3 3237/4885CYP1A2 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.